LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3)..

LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM).

LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4.

LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM.

LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM.

LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM.

Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM. IC50 Value: 7 nM [1] Target: Lck in vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (I

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LC-1028 (LC1028) is a novel potent selective, covalent and irreversible inhibitor of p97 (valosin-containing protein), remains essentially irreversible ac tivity against p97 mutant C522A..

LB42908 is a highly potent, selective, orally active inhibitor of Ras farnesyltransferase (FTase) with IC50 of 0.9 nM against H-Ras and 2.4 nM against K-Ras..

Lauric Acid is a saturated medium-chain fatty acid with a 12-carbon backbone. Lauric acid is found naturally in various plant and animal fats and oils, and is a major component of coconut oil and palm kernel oil.

LAS195319 (LAS-195319) is a potent, selective, inhaled PI3Kδ inhibitor with IC50 of 0.5 nM, weakly inhibits PI3Kβ and γ (>20-fold), no activity against PI3Kα.

Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

Lanperisone (NK 433) is a centrally acting muscle relaxant that selectively kills of K-ras mutant cancer cells in a cell cycle-independent fashion.

LAF389 is a potent methionine aminopeptidase (MetAP) inhibitor with IC50 of 800 nM for MetAP-2, inhibits both MetAp1 and 2, potently inhibits HUVEC proliferation with IC50 of 20 nM.

Lactimidomycin is a glutarimide antibiotic that has antifungal, antiviral and anti-cancer properties, acting as a direct inhibitor of protein translation in ribosomes.

Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.

L-826,266 is a potent and selective competitive antagonist of the prostaglandin E2 receptor subtype EP3 (Ki = 0.8 nM).

L-364373 (R-L3) is a stereospecific activator of cardiac slowly activating delayed rectifier K+ current (IKs) and KV7.1 (KCNQ1) channels.

L-338192 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 29 uM in AlphaScreen assay.

L-291 (DDAH-1 inhibitor L-291) is a selective, competitive DDAH1 inhibitor with IC50 of <25 uM.

L-257 (DDAH-1 inhibitor L-257) is a selective, competitive DDAH1 inhibitor with IC50 of <25 uM.

L 873724 is a potent and selective non-basic cathepsin K inhibitor with IC50 of 0.2 nM, shows no significant potency against Cat B, L, and S (IC50= 5239, 264, and 178 nM).

KZR-504 is a highly selective and orally active inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2), with IC50s of 51 nM, 4.274 μM for LMP2 and LMP7, respectively.

Kynurenic acid, a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist.

KY-04045 is a novel PAK4 inhibitor with IC50 of 8.7 uM, a basic building block in designing novel imidazo[4,5-b]pyridine-based PAK4 inhibitors..

KY-02327 is an orally active, small molecule inhibitor of the Dishevelled (Dvl)-CXXC5 interaction with IC50 of 3.1 uM, a metabolically stabilized KY-02061 analog.

KY-02061 is a small-molecule inhibitor of Dishevelled-CXXC5 interaction with IC50 of 24 uM in vitro binding assay.